Butterworth 1971a.

Methods	Randomized, double‐blind, comparative trial
Participants	39 people with alcohol dependence (all men; mean age: information not available) with a significant degree of anxious‐depressive symptomatology. Inclusion criteria: aged 20‐55 years significant degree of anxiety and depression as determined by psychiatric interview current diagnosis of alcohol dependence Exclusion criteria: physical brain liver illnesses psychotic disorder Participants with bipolar disorder: information not available
Interventions	Drugs: doxepin (75 mg/day; 20 participants, all men; mean age: 45 years) diazepam (15 mg/day; 19 participants, all men; mean age: 41 years) Psychotherapy: information not available Scheduled duration of treatment: 3 weeks Site: Alcoholism Treatment Service of East Louisiana State Hospital, Mandeville, LA, USA Setting: inpatients Route of administration: orally Starting dose: information not available Pattern of dose reduction: information not available
Outcomes	Depression: final BPRS score final ZUNG score response Alcohol dependence: data not available Dropouts Adverse effects
Notes	Baseline characteristics of participants Depression: primary depression: information not available duration: information not available BPRS score (mean): doxepin = 76.3; diazepam = 73.8 ZUNG score (mean): doxepin = 47.8; diazepam = 37.9 Alcohol dependence: severity: information not available being actively drinking: participants not actively drinking Other psychiatric comorbidity: information not available Other substance‐use disorders: information not available Other characteristics of study Other pharmacological treatment: other concomitant therapy not allowed Funding source: medications were supplied by Laboratories of Pfizer Inc. Declaration of interest: information not available
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random allocation stated. No further details provided.
Allocation concealment (selection bias)	Unclear risk	Method of concealment not described.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind stated. Medications prepared to appear identical. Evaluations conducted by 2 independent investigators and the results pooled.
Blinding of outcome assessment (detection bias) objective	Low risk	No information on blinding of outcome assessors.
Blinding of outcome assessment (detection bias) subjective	Unclear risk	No information on blinding of outcome assessors.
Incomplete outcome data (attrition bias) All outcomes	High risk	No information on dropouts provided. Methods applied to account for missing data not described. Intention‐to‐treat approach not reported.
Selective reporting (reporting bias)	High risk	No information on dropouts provided. Methods applied to account for missing data not described. Intention‐to‐treat approach not reported.